| 心血管疾病新药阿齐沙坦酯的药理与临床评价 |
| |
| 引用本文： | 赵春艳,王京晶,刘洋,赵颖辉,戴金梅.心血管疾病新药阿齐沙坦酯的药理与临床评价[J].中国新药杂志,2011(19). |
| |
| 作者姓名： | 赵春艳 王京晶 刘洋 赵颖辉 戴金梅 |
| |
| 作者单位： | 辽宁中医药大学附属第二医院;沈阳亿灵医药科技有限公司; |
| |
| 摘 要： | 阿齐沙坦酯(azilsartan medoxomil)是一种血管紧张素II受体拮抗剂,用于治疗高血压,可与其他抗高血压药物联用。本文参照美国FDA有关该药的申报资料,对其药理作用、药代动力学、临床评价、安全性评价及药物相互作用等进行综述。
|
| 关 键 词： | 阿齐沙坦酯 高血压 药理学 药代动力学 临床评价 |
Pharmacology and clinical evaluation of edarbi,a new drug for the treatment of cardiovascular disease |
| |
| ZHAO Chun-yan,WANG Jing-jing,LIU Yang,ZHAO Ying-hui,DAI Jin-mei.Pharmacology and clinical evaluation of edarbi,a new drug for the treatment of cardiovascular disease[J].Chinese Journal of New Drugs,2011(19). |
| |
| Authors: | ZHAO Chun-yan WANG Jing-jing LIU Yang ZHAO Ying-hui DAI Jin-mei |
| |
| Institution: | ZHAO Chun-yan1,WANG Jing-jing2,LIU Yang2,ZHAO Ying-hui2,DAI Jin-mei2(1 The Affiliated Second Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110034,China,2 E·living Pharmacelitical Company Ltd.of Shenyang,Shenyang 110179,China) |
| |
| Abstract: | Azilsartan medoxomil is an angiotensin II receptor blocker indicated for the treatment of hypertension.Azilsartan medoxomil can be used either alone or in combination with other antihypertensive agents.Based on the drug reporting information from the U.S.FDA,the pharmacology,pharmacokinetics,clinical evaluation,safety evaluation and drug interactions of edarbi were reviewed. |
| |
| Keywords: | azilsartan medoxomil hypertension pharmacology pharmacokinetics clinical evaluation |
| 本文献已被 CNKI 等数据库收录！ |
|
